Details of the Drug Combination

General Information of Drug Combination (ID: DCBM6TY)

Drug Combination Name
Pargyline Trimethobenzamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Pargyline   DMM0HR1 Trimethobenzamide   DMPP4DT
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.19
Bliss Independence Score: 4.19
Loewe Additivity Score: 16.2
LHighest Single Agent (HSA) Score: 16.22

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pargyline
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Muscular dystrophy 8C70 Patented [3]
Skin imperfections EK71 Patented [3]
Pargyline Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [3]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Trimethobenzamide
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [4]
Nausea and vomiting MD90 Approved [2]
Vomiting MD90 Approved [4]

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
4 Trimethobenzamide FDA Label
5 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.